Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
1475 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia - Pipeline Review, H2 2016, provides an overview of the Acute Myelocytic Leukemia (Oncology) pipeline landscape. Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Acute Myelocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 15, 91, 90, 1, 6, 143, 22 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 14, 14, 24 and 10 molecules, respectively. Acute Myelocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (Oncology). - The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Acute Myelocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 10 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Overview 11 Therapeutics Development 12 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Development by Companies 14 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes 32 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Products Glance 35 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Development by Companies 39 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Investigation by Universities/Institutes 72 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development 77 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment 287 Drug Profiles 336 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects 1388 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products 1408 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones 1415 Appendix 1428
List of Tables
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2016 58 Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H2 2016 59 Number of Products under Development by Companies, H2 2016 61 Number of Products under Development by Companies, H2 2016 (Contd..1) 62 Number of Products under Development by Companies, H2 2016 (Contd..2) 63 Number of Products under Development by Companies, H2 2016 (Contd..3) 64 Number of Products under Development by Companies, H2 2016 (Contd..4) 65 Number of Products under Development by Companies, H2 2016 (Contd..5) 66 Number of Products under Development by Companies, H2 2016 (Contd..6) 67 Number of Products under Development by Companies, H2 2016 (Contd..7) 68 Number of Products under Development by Companies, H2 2016 (Contd..8) 69 Number of Products under Development by Companies, H2 2016 (Contd..9) 70 Number of Products under Development by Companies, H2 2016 (Contd..10) 71 Number of Products under Development by Companies, H2 2016 (Contd..11) 72 Number of Products under Development by Companies, H2 2016 (Contd..12) 73 Number of Products under Development by Companies, H2 2016 (Contd..13) 74 Number of Products under Development by Companies, H2 2016 (Contd..14) 75 Number of Products under Development by Companies, H2 2016 (Contd..15) 76 Number of Products under Development by Companies, H2 2016 (Contd..16) 77 Number of Products under Investigation by Universities/Institutes, H2 2016 78 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 79 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 80 Comparative Analysis by Late Stage Development, H2 2016 81 Comparative Analysis by Clinical Stage Development, H2 2016 82 Comparative Analysis by Early Stage Development, H2 2016 83 Comparative Analysis by Unknown Stage Development, H2 2016 84 Products under Development by Companies, H2 2016 85 Products under Development by Companies, H2 2016 (Contd..1) 86 Products under Development by Companies, H2 2016 (Contd..2) 87 Products under Development by Companies, H2 2016 (Contd..3) 88 Products under Development by Companies, H2 2016 (Contd..4) 89 Products under Development by Companies, H2 2016 (Contd..5) 90 Products under Development by Companies, H2 2016 (Contd..6) 91 Products under Development by Companies, H2 2016 (Contd..7) 92 Products under Development by Companies, H2 2016 (Contd..8) 93 Products under Development by Companies, H2 2016 (Contd..9) 94 Products under Development by Companies, H2 2016 (Contd..10) 95 Products under Development by Companies, H2 2016 (Contd..11) 96 Products under Development by Companies, H2 2016 (Contd..12) 97 Products under Development by Companies, H2 2016 (Contd..13) 98 Products under Development by Companies, H2 2016 (Contd..14) 99 Products under Development by Companies, H2 2016 (Contd..15) 100 Products under Development by Companies, H2 2016 (Contd..16) 101 Products under Development by Companies, H2 2016 (Contd..17) 102 Products under Development by Companies, H2 2016 (Contd..18) 103 Products under Development by Companies, H2 2016 (Contd..19) 104 Products under Development by Companies, H2 2016 (Contd..20) 105 Products under Development by Companies, H2 2016 (Contd..21) 106 Products under Development by Companies, H2 2016 (Contd..22) 107 Products under Development by Companies, H2 2016 (Contd..23) 108 Products under Development by Companies, H2 2016 (Contd..24) 109 Products under Development by Companies, H2 2016 (Contd..25) 110 Products under Development by Companies, H2 2016 (Contd..26) 111 Products under Development by Companies, H2 2016 (Contd..27) 112 Products under Development by Companies, H2 2016 (Contd..28) 113 Products under Development by Companies, H2 2016 (Contd..29) 114 Products under Development by Companies, H2 2016 (Contd..30) 115 Products under Development by Companies, H2 2016 (Contd..31) 116 Products under Development by Companies, H2 2016 (Contd..32) 117 Products under Investigation by Universities/Institutes, H2 2016 118 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 119 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 120 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 121 Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 122 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H2 2016 123 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H2 2016 124 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H2 2016 125 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 126 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 127 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics Sarl, H2 2016 128 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H2 2016 129 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 130 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H2 2016 131 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H2 2016 132 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H2 2016 133 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H2 2016 134 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Akinion Pharmaceuticals AB, H2 2016 135 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Alexion Pharmaceuticals Inc, H2 2016 136 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Altor BioScience Corp, H2 2016 137 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc, H2 2016 138 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express Inc, H2 2016 139 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Ltd, H2 2016 140 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H2 2016 141 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea AB, H2 2016 142 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by arGEN-X BV, H2 2016 143 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H2 2016 144 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arno Therapeutics Inc, H2 2016 145 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals Inc, H2 2016 146 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Array BioPharma Inc, H2 2016 147 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astellas Pharma Inc, H2 2016 148 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Asterias Biotherapeutics Inc, H2 2016 149 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 150 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca Plc, H2 2016 151 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Atara Biotherapeutics Inc, H2 2016 152 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Athenex Inc, H2 2016 153 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 154 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 155 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bayer AG, H2 2016 156 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BCI Pharma, H2 2016 157 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 158 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BerGenBio AS, H2 2016 159 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 160 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Path Holdings Inc, H2 2016 161 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioInvent International AB, H2 2016 162 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioLineRx Ltd, H2 2016 163 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioSight Ltd, H2 2016 164 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Blueprint Medicines Corp, H2 2016 165 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 166 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boston Biomedical Inc, H2 2016 167 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H2 2016 168 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Calithera Biosciences Inc, H2 2016 169 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2016 170 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantargia AB, H2 2016 171 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantex Pharmaceuticals Inc, H2 2016 172 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cascadian Therapeutics Inc, H2 2016 173 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celgene Corp, H2 2016 174 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellceutix Corp, H2 2016 175 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celldex Therapeutics Inc, H2 2016 176 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellectar Biosciences Inc, H2 2016 177 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellectis SA, H2 2016 178 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellerant Therapeutics Inc, H2 2016 179 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celyad SA, H2 2016 180 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CharlestonPharma LLC, H2 2016 181 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cielo Therapeutics Inc, H2 2016 182 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Constellation Pharmaceuticals Inc, H2 2016 183 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 184 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Critical Outcome Technologies Inc, H2 2016 185 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CrystalGenomics Inc, H2 2016 186 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 187 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CTI BioPharma Corp, H2 2016 188 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 189 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 190 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DC Prime BV, H2 2016 191 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 192 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DiNonA Inc, H2 2016 193 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eisai Co Ltd, H2 2016 194 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eli Lilly and Company, H2 2016 195 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Emercell SAS, H2 2016 196 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EntreChem SL, H2 2016 197 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EpiZyme Inc, H2 2016 198 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Erytech Pharma SA, H2 2016 199 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Esperance Pharmaceuticals Inc, H2 2016 200 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Exelixis Inc, H2 2016 201 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 202 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fate Therapeutics Inc, H2 2016 203 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by FLX Bio Inc, H2 2016 204 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by FORMA Therapeutics Inc, H2 2016 205 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Formula Pharmaceuticals Inc, H2 2016 206 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fortress Biotech Inc, H2 2016 207 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fujifilm Corp, H2 2016 208 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gadeta BV, H2 2016 209 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gamida Cell Ltd, H2 2016 210 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genentech Inc, H2 2016 211 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genoscience Pharma, H2 2016 212 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genosco Inc, H2 2016 213 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genzyme Corp, H2 2016 214 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gilead Sciences Inc, H2 2016 215 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H2 2016 216 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlycoMimetics Inc, H2 2016 217 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Golden Biotechnology Corp, H2 2016 218 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by H3 Biomedicine Inc, H2 2016 219 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 220 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by HEC Pharm Co Ltd, H2 2016 221 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Hybrigenics SA, H2 2016 222 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Igenica Biotherapeutics Inc, H2 2016 223 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ignyta Inc, H2 2016 224 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immatics Biotechnologies GmbH, H2 2016 225 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune Pharmaceuticals Inc, H2 2016 226 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune System Key Ltd, H2 2016 227 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunGene Inc, H2 2016 228 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunoGen Inc, H2 2016 229 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immunomedics Inc, H2 2016 230 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Incyte Corp, H2 2016 231 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Inflection Biosciences Ltd, H2 2016 232 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Interprotein Corp, H2 2016 233 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Io Therapeutics Inc, H2 2016 234 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by IPD Therapeutics BV, H2 2016 235 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jasco Pharmaceuticals LLC, H2 2016 236 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jazz Pharmaceuticals Plc, H2 2016 237 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 238 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Johnson & Johnson, H2 2016 239 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Juno Therapeutics Inc, H2 2016 240 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by JW Pharmaceutical Corp, H2 2016 241 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kainos Medicine Inc, H2 2016 242 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Karyopharm Therapeutics Inc, H2 2016 243 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kiadis Pharma NV, H2 2016 244 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kite Pharma Inc, H2 2016 245 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Komipharm International Co Ltd, H2 2016 246 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 247 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Lead Discovery Center GmbH, H2 2016 248 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Les Laboratoires Servier SAS, H2 2016 249 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MacroGenics Inc, H2 2016 250 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Mateon Therapeutics Inc, H2 2016 251 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MaxCyte Inc, H2 2016 252 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by medac GmbH, H2 2016 253 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MediGene AG, H2 2016 254 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Medivation Inc, H2 2016 255 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MEI Pharma Inc, H2 2016 256 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck & Co Inc, H2 2016 257 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck KGaA, H2 2016 258 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merus NV, H2 2016 259 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Mesoblast Ltd, H2 2016 260 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 261 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by miRagen Therapeutics Inc, H2 2016 262 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Moleculin Biotech Inc, H2 2016 263 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MolMed SpA, H2 2016 264 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Nanovalent Pharmaceuticals Inc, H2 2016 265 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NantKwest Inc, H2 2016 266 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Nemucore Medical Innovations Inc, H2 2016 267 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Nerviano Medical Sciences Srl, H2 2016 268 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Neumedicines Inc, H2 2016 269 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NewLink Genetics Corp, H2 2016 270 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Novartis AG, H2 2016 271 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NuCana BioMed Ltd, H2 2016 273 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Omeros Corp, H2 2016 274 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoImmune Inc, H2 2016 275 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onconova Therapeutics Inc, H2 2016 276 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oncopeptides AB, H2 2016 277 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoTartis Inc, H2 2016 278 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoTherapy Science Inc, H2 2016 279 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oncternal Therapeutics Inc, H2 2016 280 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 281 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Otsuka Holdings Co Ltd, H2 2016 282 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oxford BioTherapeutics Ltd, H2 2016 283 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Panther Biotechnology Inc, H2 2016 284 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Petra Pharma Corp, H2 2016 285 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pfizer Inc, H2 2016 286 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharma Mar SA, H2 2016 287 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmascience Inc, H2 2016 288 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmedartis GmbH, H2 2016 289 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Philogen SpA, H2 2016 290 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Phylogica Ltd, H2 2016 291 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Polaris Pharmaceuticals Inc, H2 2016 292 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ProNAi Therapeutics Inc, H2 2016 293 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Resverlogix Corp, H2 2016 294 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Rich Pharmaceuticals Inc, H2 2016 295 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sanofi, H2 2016 296 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sareum Holdings Plc, H2 2016 297 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Seattle Genetics Inc, H2 2016 298 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sellas Inc, H2 2016 299 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Selvita SA, H2 2016 300
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
